ABSTRACT
INTRODUCTION Ventricular arrhythmia is commonly encountered in patients with dilated cardiomyopathy (IDCM) occurring in 60-87% of patients.1 Its incidence increases with left ventricular (LV) function deterioration. Moreover; it accounts for 8-50% of cardiac death in that subset of patients. Besides the conventional therapy for LV dysfunction, management of ventricular arrhythmia requires a hybrid therapy of anti-arrhythmic drugs, implantable defibrillators, and ablation therapy.2
